(CNN Español) – The AstraZeneca vaccine and the Oxford University will be able to reduce coronavirus transmission and prevent synthetic transmission, allowing researchers to publish it in a pre-publication.
Although its effectiveness is less than other vacancies approved for the prevention of symptomatic infection, it is the only one that, at the moment, has demonstrated a reduction in transmission. Doctor Elmer Huerta analyzes the results of the study in this episode.
MIRA: The Oxford / AstraZeneca vaccine could reduce coronavirus transmission, United Kingdom investigators say
You can listen to this episode on Apple Podcasts, Spotify or your favorite podcast platform, or learn the transcription and continuation.
Hello, soy, dr. Elmer Huerta and this is his diary dose of information about the new coronavirus. Information that we hope will be useful to take care of his health and that of his family.
We will see the results obtained by the AstraZeneca booth, and will announce a pre-release on February 3rd.
The vacancies and their objectives
It is doubtful that the main objective of a vacancy is to prevent the contagion of a nurse.
In other words, for example, if a child is vaccinated against the infection, the main objective of that infection is that, in contact with the virus of the infection, the victim is protected and does not suffer.
But in addition to this objective skoolhoof, there are other secondary objectives in a evacuation program.
For example, you can make sure that the person being evacuated does not have complete protection and can become infected and develop a life-threatening form. In this case, what the vaccine does is prevent serious cases and hospitalizations caused by illness.
In the same way, if you do not require complete protection, you may find that the person evacuated becomes infected, in order to develop an asymptomatic form of the disease. In this case, it is very important to know if these people with asymptomatic disease are able to transmit the disease.
The vacancy of AstraZeneca: the results of the study
In AstraZeneca’s study, investigators found that their vaccine showed an efficacy of 66.7% in preventing the symptomatic effects of the second dose after the second dose.
But in a very important way, the investigation appears to demonstrate that the vaccine is capable of reducing the transmission of the new coronavirus substantially in addition to preventing the synthetic disease.
For this purpose, PCR testing is performed in a group of participants and we find that the positive test bag is reduced after the dose of the vaccine dose, and after a single dose, the positive test bag is reduced by 67% .
This hecho, aun no demonstrated for the vacerna of Moderna and Pfizer, is very important can help much in the eradication of the sick.
In another important case, the investigation indicates that the vaccine is able to protect against infection after a single injection, with an efficacy of 76% from day 22 to day 90 after having administered the first dose.
Respectively, the study states that the antidote levels during this time period are relatively established, with a minimum reduction of the antidotes in day 90.
The dose of AstraZeneca vaccine
It is important to note that, based on the political decision taken by the British government in the last week of December 2020, to approve AstraZeneca’s emergence use, it will be worldwide and recommend the second dose. darse 12 weeks ago.
The hecho of which the levels of anticoagulation are hayan mantenido establishles, with a minimum reduction of these substances 3 months after a single dose, justifies without doubt that it can be evacuated with the first dose to the maximum possible number of persons, hoping to have up to 3 months for the second time, giving time to the production of vacancies can be agilized.
In summary, this study indicates that AstraZeneca’s vaccine alone is not capable of slowing down the transmission of the virus, meaning that it is possible to delay the second dose up to 12 weeks after the first.
The pre-publication is located in its revision by pares in the medical review The Lancet.
Do you have any questions about coronavirus?
We will post your questions on Twitter, we will respond to our upcoming episodes. You can find in @DrHuerta. You have not responded yet.
If you think this podcast is useful, you can help others find, rate and revise it in your favorite podcast application. Volveremos mañana, as well as making sure to subscribe to get the ultimate episode on your account.
For more information, please send a CNNEspanol.com. Thank you for your attention.